

Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

CIN: L24230GJ1992PLC017820

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4, Opp. PCI, Ankleshwar – 393 002, Gujarat, India Tel : (02646) 220774 Fax : (02646) 251291 Web: www.samratpharmachem.com **Corporate Office**

701/702, Business Square, M. A. Road, Andheri (West), Mumbai – 400 058, India. Tel : (91-22) 26701050/1/2 Fax : (91-22) 26701053 E: contact@samratpharmachem.in

October 20, 2020

To, Department of Corporate Services, BSE Limited 25th Floor, P J Towers, Dalal Street, Mumbai - 400 001.

Dear Sir,

Sub: Reconciliation of Share Capital Audit f.t.q.e. 30/09/2020

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are forwarding herewith a Certificate issued by Practicing Company Secretary after conducting Reconciliation of Share Capital Audit for the quarter ended September 30, 2020.

Thanking you,

Yours faithfully, For Samrat Pharmachem Limited

Nishant Kankaria Company Secretary & Compliance Officer

Aqueel A. Mulla

B.Com., L.L.M., F.C.S., A.G.P. (U.K.)., D.I.T., Ph.D

A. A. MULLA & ASSOCIATES Company Secretaries

Room No.603, A Wing, 6th Floor, Dhamm Seva CHS, Deluxe Building, Opp. Kurla Station East, Mumbai – 400 024. M: 9892237418 Email: aqueelmulla@gmail.com

October 20, 2020

The Board of Directors, M/s. Samrat Pharmachem Limited Plot No. A2/3445, GIDC, Phase 4, Ankleshwar – 393 002, <u>Gujarat</u>.

Dear Sir,

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are enclosing herewith a Certificate issued by us after conducting Reconciliation of Share Capital Audit for the quarter ended **30th September, 2020**, as required under the said circular.

Please find the same in order & forward a copy of the same to the respective stock exchanges.

Yours faithfully, For A.A. Mulla & Associates Company Secretaries

Aqueel A. Mulla Proprietor

UDIN: F002973B000522910



Reconciliation of Share Capital Audit Report

(As per Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018).

Sr. No	Particulars	Details				
1.	For Quarter Ended	30 th September, 2020				
2.	ISIN	INE103E01016				
3.	Face Value	Rs. 10				
4.	Name of the Company	Samrat Pharmachem Limit	red			
5.	Registered Office Address	Plot No. A2/3445,				
		GIDC, Phase 4,				
		Ankleshwar $-393\ 002$,				
		Gujarat.				
6.	Correspondence Address	701/702, Business Square,				
		M. A. Road,				
		Andheri (West),				
		Mumbai – 400 058.				
7.	Tel No. & Fax No.	Tel : (022) 26701050				
	P. 1.4.11	Fax : (022) 26701053				
8.	Email Address	contact@samratpharmachem.in				
9.	Website	www.samratpharmachem.com				
9.	Names of the stock exchanges where the	Mumbai				
10.	company's securities are listed. Issued Capital	No. of shares % of total issued capital				
10.	Issued Capital	No. of shares% of total issued capital30,89,700100.00 %				
11.	Listed Capital (Exchange Wise)	50,89,700	100.00 /0			
11.	As per company records	30,89,700 100.00 %				
	 It is same for all the exchanges 	50,67,700 100.00 /0				
12.	Held in dematerialized form in CDSL	4,34,634 14.07 %				
13.	Held in dematerialized form in NSDL	22,90,156 74.12 %				
14.	Physical	3,64,910	11.81 %			
15.	Total No. of shares (12+13+14)	30,89,700	100.00 %			
16.	Reasons for difference if any, between (10&11), (10&15), (11&15)	Nil				

17. Certifying the details of changes in share capital during the quarter under consideration as per table below:

Particulars ***	No. of shares	Applied / Not applied for listing	Listed on stock exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (Specify Names)
Nil	Nil	Nil	Nil	Nil	Nil	Nil

*** Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify)

18.	Registrar of members is updated (Yes/No)	Yes	WIMBAL WIMBAL COP No. 22777 *
	If not, updated upto which date	Not Applicable	Could Margan

- 19. Reference of previous quarter with regards to excess de-materialised shares, if any.
- 20. Has the Company resolved the matter mentioned in Point No. 19 above in the current quarter ? If not, reason why ?

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay :

Total No. of demat requests	No. of requests	No. of shares	Reason for delay
Confirmed after 21 days	0	0	-
Pending for more than 21 days	0	0	-

22.	Name, Tel No., Fax No. & Membership	Name	:	Mr. Nishant Anandkumar Kankaria
	No. of the Compliance Officer of the Co.	Tel No.	:	(91-22) 26701050
		Fax No.	:	-
		Membership	:	ACS-59905
		No.		
		Email	:	contact@samratpharmachem.in

23.	Name, Address, Tel No. & Fax No., Regn No. of the Certifying CA/CS	Name	: A. A. Mulla & Associates Company Secretaries
		Address	: Room No.603, A Wing, 6th Floor, Dhamm Seva CHS, Deluxe Building, Opp Kurla Station East, Mumbai-400024
		Tel No.	: (91) 9892237418
		Email	: aqueelmulla@gmail.com

24.	Appointment of common agency for	Name	:	Link Intime India Pvt Ltd
	share registry work	Address	:	C-101, 247 Park,
				L. B. S. Marg, Vikhroli (West),
				Mumbai – 400 083, Maharashtra.
		Tel No.	:	(022) 49186000
		Fax No.	:	(022) 49186060
		Email	:	rnt.helpdesk@linkintime.co.in
		Kind Attn	:	Ms. Shweta Poojari

25. Any other detail that the CA/CS may like to provide (eg BIFR Company, de-listing from SE, etc)

Date : October 20, 2020 Place : Mumbai

For A. A. Mulla & Associates Company Secretaries



Aqueel A Mulla Proprietor C.P. No. 3237 CS No. 2973 UDIN: F002973B001004655